Essential Fatty Acids Based Therapeutic Approach to Sepsis and other Inflammatory Conditions
There is limited success with the use of steroids, antibiotics, and activated protein C in sepsis, suggesting that an “out of the box thinking and approaches” are needed. Previously, we showed that an altered metabolism of essential fatty acids (EFAs) occurs in sepsis. Plasma phospholipid concentrations of gamma-linolenic acid (GLA, 18:3 n-6), dihomo-GLA (20:3 n-6), arachidonic acid (AA, 20:4 n-6), alpha-linolenic acid (ALA, 8:3 n-3), and eicosapentaenoic acid (EPA, 20:5 n-3) derived from EFAs: cis-linoleic acid (LA) and α-linolenic acid (ALA) have been found to be decreased in sepsis. GLA, DGLA, AA, EPA and DHA are precursors of both pro-inflammatory and anti-inflammatory eicosanoids. It is likely that an imbalance between these pro- and anti-inflammatory eicosanoids may play a significant role in sepsis. Lipoxin A4 (LXA4), an anti-inflammatory metabolite derived from AA augments neutrophil phagocytosis, enhances survival and augments resolution of inflammation in sepsis. Prostaglandin E1 (PGE1), derived from DGLA, enhances LXA4 generation and has actions like LXA4. Corticosteroids and interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) that are present in large amounts in plasma of those with sepsis interfere with the metabolism of EFAs. It is proposed that restoring the balance between pro- and anti-inflammatory eicosanoids may form a novel approach in the management of sepsis and other inflammatory conditions.
Authors
- Undurti Narasimha Das (ORCID: https://orcid.org/0000-0002-0191-9508)
Publication Details
- Journal
- Recent trends in pharmacology.
- Published
- 2026-11-19
- DOI
- https://doi.org/10.62425/rtpharma.2037280
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00